Evidence map›Paper›PMID 27141290›Full record

ReviewTherapeutic advances in psychopharmacology2016

Multiple D2 heteroreceptor complexes: new targets for treatment of schizophrenia.

Dasiel O Borroto-Escuela, Julia Pintsuk, Thorsten Schäfer, Kristina Friedland, Luca Ferraro, Sergio Tanganelli, Fang Liu, Kjell Fuxe

Open access · bronzeAbstract readReview
In one paragraph

Review in Therapeutic advances in psychopharmacology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
5.6field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 53 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Impact of an Adenosine AMolecular pharmaceutics · 2022
    Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Targeting Dopamine DThe Journal of pharmacology and experimental therapeutics · 2019
    Article
  16. Review
  17. Article
  18. Dopamine DThe Journal of pharmacology and experimental therapeutics · 2018
    Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 6 institutions in 5 countries.

Dasiel O Borroto-EscuelaDepartment of Neuroscience, Karolinska Institutet, Stockholm, Sweden Department of Biomolecular Science, Section of Physiology, University of Urbino, Italy.
Julia PintsukDepartment of Neuroscience, Karolinska Institutet, Stockholm, Sweden Institute of Biomedicine and Translational Medicine, University of Tartu, Estonia.
Thorsten SchäferClinical and Molecular Pharmacy, Department of Chemistry and Pharmacy, Friedrich Alexander University, Erlangen-Nürnberg, Germany.
Kristina FriedlandClinical and Molecular Pharmacy, Department of Chemistry and Pharmacy, Friedrich Alexander University, Erlangen-Nürnberg, Germany.
Luca FerraroDepartment of Life Sciences and Biotechnology, University of Ferrara, Italy.
Sergio TanganelliDepartment of Life Sciences and Biotechnology, University of Ferrara, Italy Department of Medical Sciences, University of Ferrara, Italy.
Fang LiuCampbell Research Institute, Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario, Canada.
Kjell FuxeDepartment of Neuroscience, Karolinska Instituet, Retzius väg 8, 17177 Stockholm, Sweden.
Friedrich-Alexander-Universität Erlangen-Nürnberg · DEUniversity of Ferrara · ITCentre for Addiction and Mental Health · CAKarolinska Institutet · SEUniversity of Tartu · EEUniversity of Urbino · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The dopamine (DA) neuron system most relevant for schizophrenia is the meso-limbic-cortical DA system inter alia densely innervating subcortical limbic regions. The field of dopamine D2 receptors and schizophrenia changed markedly with the discovery of many types of D2 heteroreceptor complexes in subcortical limbic areas as well as the dorsal striatum. The results indicate that the D2 is a hub receptor which interacts not only with many other G protein-coupled receptors (GPCRs) including DA isoreceptors but also with ion-channel receptors, receptor tyrosine kinases, scaffolding proteins and DA transporters. Disturbances in several of these D2 heteroreceptor complexes may contribute to the development of schizophrenia through changes in the balance of diverse D2 homo- and heteroreceptor complexes mediating the DA signal, especially to the ventral striato-pallidal γ-aminobutyric acid (GABA) pathway. This will have consequences for the control of this pathway of the glutamate drive to the prefrontal cortex via the mediodorsal thalamic nucleus which can contribute to psychotic processes. Agonist activation of the A2A protomer in the A2A-D2 heteroreceptor complex inhibits D2 Gi/o mediated signaling but increases the D2 β-arrestin2 mediated signaling. Through this allosteric receptor-receptor interaction, the A2A agonist becomes a biased inhibitory modulator of the Gi/o mediated D2 signaling, which may the main mechanism for its atypical antipsychotic properties especially linked to the limbic A2A-D2 heterocomplexes. The DA and glutamate hypotheses of schizophrenia come together in the signal integration in D2-N-methyl-d-aspartate (NMDA) and A2A-D2-metabotropic glutamate receptor 5 (mGlu5) heteroreceptor complexes, especially in the ventral striatum. 5-Hydroxytryptamine 2A (5-HT2A)-D2 heteroreceptor complexes are special targets for atypical antipsychotics with high potency to block their 5-HT2A protomer signaling in view of the potential development of pathological allosteric facilitatory 5-HT2A-D2 interaction increasing D2 protomer signaling. Neurotensin (NTS1)-D2 heterocomplexes also exist in the ventral and dorsal striatum, and likely also in midbrain DA nerve cells as NTS1-D2 autoreceptor complexes where neurotensin produces antipsychotic and propsychotic actions, respectively.

Indexed as

allosteric receptor–receptor interactionsdopamine receptorsG protein-coupled receptorsheteroreceptor complexesneurotensin receptorspsychotic disordersschizophreniaserotonin receptors

Identifiers

PMID27141290
PMCPMC4837969
OpenAlexW2314877083

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.